• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BioTechnology: An Indian Journal >Clinical study ofHuxinkang tablet in treating unstable angina pectoris
【24h】

Clinical study ofHuxinkang tablet in treating unstable angina pectoris

机译：欣欣康片治疗不稳定型心绞痛的临床研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To observe the clinical efficacy of Huxinkang Tablet on unstable angina pectoris (UAP). 65 patients ofUAPwere divided into the control group (32 cases) and treatment group (33 cases). All patients were treated with the westernmedicine. Then, patients in the control group and treatment group were administered Tongxinluo Capsule and HuxinkangTablet, respectively. The changes of clinical efficacy, angina pectoris (AP), electrocardiograph (ECG), Chinesemedicine syndrome (CMS), blood fat, homocysteine (Hcy) and high-sensitivity C-reactive protein (hs-CRP) of two groups were observed. Total effective rate of the treatment group was higher than the control group (P<0.05). The treatment group had a better curative effect of AP, ECGand CMS than the control group (P<0.05). HuxinkangTablet had better effects to improve lipid metabolismand lower the levels of Hcy and hs-CRP than the control group (P<0.05). It is effective that the clinical efficacy of Huxinkang Tablet in treating UAP.
机译：观察护心康片对不稳定型心绞痛（UAP）的临床疗效。将65例UAP患者分为对照组（32例）和治疗组（33例）。所有患者均接受西药治疗。然后，对照组和治疗组的患者分别服用通心络胶囊和护心康片剂。观察两组患者的临床疗效，心绞痛（AP），心电图（ECG），中医证候（CMS），血脂，高半胱氨酸（Hcy）和高敏C反应蛋白（hs-CRP）的变化。治疗组总有效率高于对照组（P <0.05）。治疗组AP，ECG和CMS的疗效均优于对照组（P <0.05）。与对照组相比，呼心康片对改善脂质代谢，降低Hcy和hs-CRP水平具有更好的效果（P <0.05）。护心康片治疗UAP有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号